NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board
NeuroNOS, a Beyond Air (NASDAQ: XAIR) subsidiary, has appointed Nobel Prize laureate Professor Dan Shechtman to its Scientific Advisory Board. Shechtman, who won the 2011 Nobel Prize in Chemistry for discovering quasicrystals, joins fellow Nobel laureate Professor Roger Kornberg in advancing treatments for Autism Spectrum Disorder (ASD) and Alzheimer's Disease (AD).
The company's proprietary platform combines behavioral techniques, AI, and wet lab capabilities to develop neurological disorder treatments. NeuroNOS is currently conducting preclinical studies to support an FDA IND application, with plans to begin first-in-human clinical trials for ASD in 2026. Their lead drug candidate, BA-102, is advancing through preclinical development.
Professor Shechtman, currently a Distinguished Professor at the Technion, brings expertise in materials science, structural chemistry, and innovation to strengthen the company's scientific capabilities.
NeuroNOS, una società controllata di Beyond Air (NASDAQ: XAIR), ha nominato il premio Nobel Professor Dan Shechtman nel suo Comitato Scientifico Consultivo. Shechtman, vincitore del Premio Nobel per la Chimica 2011 per la scoperta dei quasicristalli, si unisce al collega premio Nobel Professor Roger Kornberg per promuovere trattamenti per il Disturbo dello Spettro Autistico (ASD) e la Malattia di Alzheimer (AD).
La piattaforma proprietaria dell’azienda combina tecniche comportamentali, intelligenza artificiale e capacità di laboratorio per sviluppare terapie per disturbi neurologici. NeuroNOS sta attualmente conducendo studi preclinici per supportare una domanda IND presso la FDA, con l’obiettivo di avviare le prime sperimentazioni cliniche sull’uomo per l’ASD nel 2026. Il loro principale candidato farmaco, BA-102, sta avanzando nello sviluppo preclinico.
Il Professor Shechtman, attualmente Professore Distinto al Technion, apporta competenze in scienza dei materiali, chimica strutturale e innovazione per rafforzare le capacità scientifiche dell’azienda.
NeuroNOS, una subsidiaria de Beyond Air (NASDAQ: XAIR), ha nombrado al laureado con el Premio Nobel Profesor Dan Shechtman en su Consejo Asesor Científico. Shechtman, ganador del Premio Nobel de Química 2011 por descubrir los cuasicristales, se une al también laureado Profesor Roger Kornberg para avanzar en tratamientos para el Trastorno del Espectro Autista (TEA) y la Enfermedad de Alzheimer (EA).
La plataforma propia de la compañía combina técnicas conductuales, inteligencia artificial y capacidades de laboratorio para desarrollar tratamientos para trastornos neurológicos. NeuroNOS está llevando a cabo estudios preclínicos para respaldar una solicitud IND ante la FDA, con planes de iniciar los primeros ensayos clínicos en humanos para TEA en 2026. Su principal candidato a medicamento, BA-102, avanza en el desarrollo preclínico.
El Profesor Shechtman, actualmente Profesor Distinguido en el Technion, aporta experiencia en ciencia de materiales, química estructural e innovación para fortalecer las capacidades científicas de la empresa.
NeuroNOS는 Beyond Air(NASDAQ: XAIR)의 자회사로, 노벨상 수상자인 Dan Shechtman 교수를 과학 자문 위원회에 임명했습니다. 2011년 화학 분야 노벨상을 수상한 Shechtman 교수는 준결정체를 발견한 공로로, 또 다른 노벨상 수상자인 Roger Kornberg 교수와 함께 자폐 스펙트럼 장애(ASD) 및 알츠하이머병(AD) 치료법 개발을 추진합니다.
회사의 독자적인 플랫폼은 행동 기법, 인공지능, 실험실 역량을 결합하여 신경학적 질환 치료제를 개발하고 있습니다. NeuroNOS는 현재 FDA IND 신청을 지원하기 위한 전임상 연구를 진행 중이며, 2026년 ASD 대상 최초 임상시험을 시작할 계획입니다. 주력 후보 약물인 BA-102는 전임상 개발 단계에 있습니다.
현재 Technion의 저명한 교수인 Shechtman 교수는 재료 과학, 구조 화학, 혁신 분야의 전문 지식을 바탕으로 회사의 과학 역량 강화를 돕고 있습니다.
NeuroNOS, une filiale de Beyond Air (NASDAQ : XAIR), a nommé le lauréat du prix Nobel Professeur Dan Shechtman à son conseil consultatif scientifique. Shechtman, qui a remporté le prix Nobel de chimie en 2011 pour la découverte des quasicristaux, rejoint le professeur Roger Kornberg, également lauréat du Nobel, pour faire progresser les traitements du trouble du spectre autistique (TSA) et de la maladie d'Alzheimer (MA).
La plateforme propriétaire de l'entreprise combine des techniques comportementales, l'intelligence artificielle et des capacités de laboratoire pour développer des traitements des troubles neurologiques. NeuroNOS mène actuellement des études précliniques afin de soutenir une demande IND auprès de la FDA, avec l'intention de débuter les premiers essais cliniques chez l'humain pour le TSA en 2026. Leur principal candidat-médicament, BA-102, progresse dans le développement préclinique.
Le professeur Shechtman, actuellement professeur distingué au Technion, apporte son expertise en science des matériaux, chimie structurale et innovation pour renforcer les capacités scientifiques de l'entreprise.
NeuroNOS, eine Tochtergesellschaft von Beyond Air (NASDAQ: XAIR), hat den Nobelpreisträger Professor Dan Shechtman in seinen Wissenschaftlichen Beirat berufen. Shechtman, der 2011 den Nobelpreis für Chemie für die Entdeckung von Quasikristallen erhielt, schließt sich dem ebenfalls mit dem Nobelpreis ausgezeichneten Professor Roger Kornberg an, um Behandlungen für Autismus-Spektrum-Störung (ASD) und Alzheimer-Krankheit (AD) voranzutreiben.
Die firmeneigene Plattform kombiniert verhaltensbasierte Techniken, KI und Laborfähigkeiten, um Therapien für neurologische Erkrankungen zu entwickeln. NeuroNOS führt derzeit präklinische Studien durch, um einen FDA-IND-Antrag zu unterstützen, mit dem Ziel, 2026 erste klinische Studien am Menschen für ASD zu starten. Ihr führender Arzneimittelkandidat, BA-102, befindet sich in der präklinischen Entwicklung.
Professor Shechtman, derzeit Distinguished Professor am Technion, bringt Expertise in Materialwissenschaften, Strukturchemie und Innovation ein, um die wissenschaftlichen Kompetenzen des Unternehmens zu stärken.
- Addition of two Nobel Prize laureates to Scientific Advisory Board strengthens research expertise
- Preclinical studies demonstrate platform effectiveness
- Development timeline on track for 2026 clinical trials
- Proprietary platform combines multiple advanced technologies
- No approved products or revenue generation yet
- Clinical trials won't begin until 2026
- Still in early preclinical stage with unproven therapeutic effectiveness
Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer’s Disease
BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and Alzheimer’s disease (AD)conditions, and a subsidiary of Beyond Air (NASDAQ: XAIR), is proud to announce the appointment of Nobel Prize laureate, Professor Dan Shechtman, to its Scientific Advisory Board (SAB).
“We are delighted to welcome Professor Shechtman to our Scientific Advisory Board,” said Amir Avniel, CEO of NeuroNOS. “The addition of Professor Shechtman, alongside Professor Roger Kornberg from Stanford University, brings unparalleled scientific expertise to our team. Having two Nobel Prize laureates guiding the NeuroNOS research team significantly enhances our capabilities and underscores our commitment to pioneering treatments for complex neurological disorders.”
NeuroNOS stands among a select group of biopharmaceutical companies exclusively dedicated to addressing complex brain disorders. The company’s proprietary platform uniquely integrates multidisciplinary tools - including high-end behavioral techniques, advanced AI, and specialized wet lab capabilities - to accelerate the development of treatments for challenging neurological disorders, such as ASD and AD. Recent preclinical studies have demonstrated the effectiveness of the NeuroNOS platform, reinforcing the company’s confidence in the potential of its platform to transform therapeutic approaches in neuropsychiatry and neurodegenerative diseases. Currently, the company is executing a series of key preclinical studies designed to support a planned IND application to the FDA. The company’s program remains on track to initiate first-in-human clinical trials for ASD in the United States in 2026. This will mark an exciting step forward in the company’s mission to transform treatment for individuals and families affected by these challenging conditions.
Professor Shechtman, who was awarded the 2011 Nobel Prize in Chemistry for his groundbreaking discovery of quasicrystals, brings decades of expertise in advanced materials science, structural chemistry, and innovation. Professor Shechtman is currently a Distinguished Professor at the Technion – Israel Institute of Technology and a globally recognized leader in materials science and crystallography. His discovery of quasicrystals revolutionized the field and challenged long-standing paradigms. Beyond his scientific achievements, Professor Shechtman is a passionate advocate for science education and innovation.
Professor Shechtman expressed his enthusiasm for joining the company’s SAB, “Science holds the key to addressing humanity’s greatest challenges. I am excited to collaborate with NeuroNOS and its team of world-class scientists to develop transformative therapies for Autism and Alzheimer’s disorders that impact millions worldwide.”
“As a Nobel Prize laureate and renowned scientist, Professor Shechtman's invaluable expertise will significantly elevate the scientific rigor at NeuroNOS. His guidance will play a pivotal role in advancing our efforts to develop the first effective treatment for the core symptoms of ASD,” said Prof. Haitham Amal, CSO of NeuroNOS, Associate Professor at The Hebrew University of Jerusalem, and Visiting Professor at Harvard Medical School. “This appointment comes at a pivotal time, as we advance our lead drug candidate BA-102 through preclinical and clinical development. The addition of Professor Shechtman’s expertise is expected to help accelerate the translation of cutting-edge science into impactful treatments.”
About NeuroNOS
NeuroNOS is at the forefront of developing innovative treatments for neurodevelopmental and neurodegenerative disorders. The company specializes in creating therapies based on small molecules that cross the blood-brain barrier to regulate Nitric Oxide (NO) levels in the brain. Preclinical studies conducted by NeuroNOS have demonstrated that NO is present at elevated levels in children with Autism Spectrum Disorder (ASD) and adults suffering from brain-related diseases such as Alzheimer’s and brain cancers. The company’s research has shown that managing NO levels in the brain is crucial for maintaining normal brain function. By leveraging this groundbreaking science, NeuroNOS aims to bring transformative therapies to those affected by these challenging conditions, ultimately improving individuals' lives. Through collaborations with leading research institutions and experts in the field, the company is committed to advancing medical innovation and delivering life-changing treatments.
For more information, please visit https://www.neuro-nos.com.
About Beyond Air, Inc.
Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous Nitric Oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections, such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. Also, the Company has partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of Autism Spectrum Disorder (ASD) and other neurological disorders. In addition, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
Forward Looking Statements
This press release contains “forward-looking statements” (as defined in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended). You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including those related to the completion of the offering, risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air undertakes no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.
Investor Relations contacts
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
FAQ
When will NeuroNOS (XAIR) begin human clinical trials for its Autism treatment?
What is NeuroNOS's lead drug candidate for Autism treatment?
How many Nobel Prize laureates are on NeuroNOS's Scientific Advisory Board?
What therapeutic areas does NeuroNOS (XAIR) focus on?
What technologies does NeuroNOS use in its drug development platform?
